Leo Pharma gains FDA nod for eczema drug Adbry, but can it challenge Sanofi and Regeneron's formidable Dupixent?
28th December 2021 Uncategorised 0 Leo Pharma gains FDA nod for eczema drug Adbry, but can it challenge Sanofi and Regeneron’s formidable Dupixent?
kdunleavy
Tue, 12/28/2021 – 11:09
More: Leo Pharma gains FDA nod for eczema drug Adbry, but can it challenge Sanofi and Regeneron's formidable Dupixent?
Source: fierce